On September 2, Yu Cuiyun, Vice President and Party Committee Member of Hunan Academy of Chinese Medicine (hereinafter referred to as the Academy), led a delegation to inspect the company's Liuyang production base. Accompanying them were Kuang Jianjun, Director of the Academy's Research Work Department and Director of the Institute of Clinical Pharmacology of Chinese Medicine, and Dr. Ling Chengli. The company's Party Branch Secretary and Chairman Shen Fanshun, along with other leadership members and production managers, also participated in the inspection.

Yu Cuiyun and her delegation toured the company's exhibition hall, production workshop, quality inspection center, and pharmaceutical research institute, gaining detailed insights into the company's production, quality control, and R&D operations.

At the symposium, Shen Fanshun highlighted the company's research achievements and production sales of innovative Chinese herbal decoctions, novel health-promoting teas, and classic prescriptions, while outlining its strategic development roadmap.

Yu Cuiyun fully affirmed the company's achievements in the transformation and upgrading of traditional Chinese medicine formula granules, and put forward requirements and suggestions for the next stage of development. First, in response to market changes and industry trends, Chun Guang Jiuhui should not only focus on the new herbal decoction piece sector but also develop flagship products based on formula granules and ultra-fine herbal decoction pieces. In the health industry emphasizing preventive care, the company should seize opportunities, boldly experiment, and continuously expand market growth. Second, as the shareholder unit, the research institute should strengthen collaboration with the company in talent cultivation, technical support, and research projects. Through joint achievements, both parties should jointly promote Chun Guang Jiuhui's expansion and competitiveness. Third, for varieties unsuitable for formula granules, the company should explore alternative approaches while preserving the unique advantages of ultra-fine herbal decoction pieces. Further research should be conducted on their safety and efficacy, supported by convincing scientific data to secure policy support from regulatory authorities. This will facilitate broader application of ultra-fine herbal decoction pieces and promote sustainable development of the traditional Chinese medicine industry.